Arimidex is an oral medication used to reduce the risk of certain cancers and blood clots in people who have a uterus. It is also used for the treatment of breast cancer.
Arimidex is available in tablets, capsules and in liquid suspension. It is usually taken once a day with or without food. Arimidex is also available as an injectable treatment for women who have a low response to hormonal treatment. It is also used as part of the treatment for men with hormone receptor-positive or -negative breast cancer.
Arimidex is a non-steroidal aromatase inhibitor, which reduces the amount of estrogen in the body. This reduction in estrogen levels can help prevent the development of breast cancer in people who have high levels of estrogen.
Arimidex is available in tablet, capsule and in liquid suspension, and can be taken once a day with or without food. Arimidex is also used as part of the treatment for women who have had an abnormal mammogram.
Arimidex is a type of medication called a thienomethionone, which means it is an inhibitor of the enzyme aromatase. When this enzyme is inhibited, the production of estrogen levels reduces.
Arimidex is a medication used to reduce the risk of certain cancers and blood clots in people who have a uterus. It is also used to prevent blood clots in people who have a uterus.
Arimidex is a non-steroidal aromatase inhibitor. This means it reduces the activity of aromatase enzyme in the body. By reducing the production of estrogen levels, this medication reduces the risk of developing a blood clot or a cancer. Aromatase is a type of steroid hormone responsible for the production of estrogen.
Arimidex can cause side effects in some people. Common side effects include nausea, diarrhea, vomiting, headache, dizziness, and headache. Other side effects may include:
If you experience side effects, it is important to seek medical help immediately.
Description:Arimidex 1mg tablet is an anticancer drug with the active ingredient Anastrozole. It belongs to the medication class and is used to treat breast cancer in postmenopausal women. Arimidex 1mg is used to treat postmenopausal breast cancer in postmenopausal women with hormone receptor-positive disease. Arimidex 1mg tablets should be taken as per the advice of the on-label.Directions:For use as directed. Take 1 tablet daily for 5 days.Formulations:Arimidex 1mg tablets are available in various forms, including oral tablets, tablets, and oral suspensions. The typical starting dose is 0.5 mg/day, taken orally with a glass of water. The dosage may be adjusted based on response. Adjustments may be made as needed, but no adjustments are made at this time.
Anastrozole
The recommended dosage of Arimidex 1mg for treatment of postmenopausal women with hormone receptor-positive breast cancer is 2 mg/day. However, the dosage may be adjusted based on response. Adjustments may be made in as little as 10 days. - Anastrozole is an aromatase inhibitor. - Take 2 tablets (500 mg) once daily. - The treatment duration is 5 days. - The maximum daily dose is 1250 mg.Contraindications:- Not recommended in patients with hypersensitivity to anastrozole or to any of the excipients. - Not recommended in patients with impaired liver or kidney function. - Not recommended in patients with severe cardiovascular or respiratory conditions. - Not recommended in patients with severe liver or kidney disease. - Not recommended in patients with active peptic ulcer. - Not recommended in patients taking tamoxifen. - Not recommended in patients with impaired contraceptive function. - Not recommended in patients with impaired hepatic function. - Not recommended in patients with active liver function. - Not recommended in patients with active stomach bleeding. - Not recommended in patients with active hepatic function. - Not recommended in patients with active breast cancer.Adverse Effects:- Nausea: 7.6% (9/133) - Headache: 6.2% (7/133) - Par skyrocket: 11.8% (11/133) - Flushing: 7.5% (5/133) - Fatigue: 5.8% (3/133) - Numbness: 3.9% (2/133) - Back pain: 2.3% (1/133) - Muscle aches: 2.3% (1/133) - Sweating: 2.3% (1/133) - Sweaty or dry mouth: 2.3% (1/133) - Dizziness: 2.3% (1/133) - Drowsiness: 2.3% (1/133) - Drowsiness: 2.3% (1/133) - Increased sweating: 2.3% (1/133) - Visual: 2.3% (1/133) - Visual: 2.3% (1/133) - Breast pain: 2.3% (1/133) - Fatigue: 2.3% (1/133) - Back pain: 2.3% (1/133) - Numbness: 2.3% (1/133) - Nausea: 2.3% (1/133) - Headache: 2.3% (1/133) - Par: 2.3% (1/133) - Flushing: 2.3% (1/133) - Nasal congestion: 2.3% (1/133) - Visual: 2.3% (1/133) - Breast pain: 2.3% (1/133) - Nausea: 2.3% (1/133) - Headache: 2.3% (1/133) - Par: 2.3% (1/133) - Fatigue: 2.3% (1/133) - Back pain: 2.3% (1/133) - Nausea: 2.3% (1/133) - Headache: 2.3% (1/133) - Par: 2.3% (1/133) - Flushing: 2.
The primary therapy for breast cancer is hormone receptor-positive disease (HR-positive). A number of compounds such as tamoxifen, aromatase inhibitors, and antiestrogen agents have been used for treating breast cancer [
,
]. Several aromatase inhibitors, including tamoxifen and anastrozole, have been reported to reduce the size of breast cancer [
The use of these agents has been associated with an increased risk of ovarian cancer, and there are no adequate and well-controlled studies in breast cancer, and no case reports on the use of aromatase inhibitors in breast cancer [
Tamoxifen has also been reported to have a slightly lower risk of breast cancer than tamoxifen [
We investigated the effect of arimidex, a synthetic compound that has been used to treat breast cancer, on the size of breast cancer in a randomized, double-blind, placebo-controlled clinical trial. Patients were randomly assigned to receive either arimidex (Arimidex, 10 mg, or placebo) or a placebo (placebo, 0.25 mg/kg or 0.5 mg/kg, twice daily) during a 6-month treatment period. Results showed that arimidex increased the size of the cancer (P = 0.038) and that the increase was statistically significant (P = 0.017). However, no significant difference was observed in terms of the ratio of cancer size to other risk factors. It is important to note that the use of arimidex is associated with an increased risk of ovarian cancer and that it may be associated with other factors that have not been studied [
Arimidex, a synthetic compound that has been used to treat breast cancer, has been reported to decrease the size of breast cancer in an animal model of endocrine-responsive disease [
Arimidex has been shown to increase the number of estrogen receptors in breast cancer cells. Furthermore, in vivo studies in a breast cancer cell line have shown that it increases the amount of estrogen and does not increase the amount of estrogen in breast tissue. In the present study, we assessed the effect of arimidex on the size of breast cancer in a human cancer cell line.
The clinical and laboratory results of the Arimidex/Placebo (placebo) trial were evaluated retrospectively. The Arimidex/Placebo trial recruited 1253 patients with hormone receptor-positive breast cancer who were randomized to receive either arimidex (n = 10) or placebo (n = 10). The baseline characteristics of the Arimidex/Placebo trial are listed in
Table 1. Baseline characteristics of patients in the Arimidex/Placebo trial
The arimidex/placebo (placebo) trial demonstrated no significant difference in the final size of the ductal carcinoma in situ (DCIS) (mean±standard deviation [SD]) and the invasive (mean±SD) clinical stage compared with the placebo group (P = 0.098). There was no difference in the final size of the ductal carcinoma in situ (DCIS) or invasive (mean±SD) clinical stage between the arimidex/placebo and placebo groups (P = 0.566 and 0.921, respectively). The Arimidex/Placebo (placebo) trial also did not demonstrate a statistically significant difference in the final size of the invasive (mean±SD) clinical stage between the arimidex/placebo and placebo groups (P = 0.921).
The arimidex/Placebo (placebo) trial also did not demonstrate a statistically significant difference in the final size of the invasive (mean±SD) clinical stage between the arimidex/placebo and placebo groups (P = 0.921).
Arimidex 1 Tablet is used to treat breast cancer in women who have gone through menopause (cessation of menses periods). Breast cancer is a type of cancer that develops in breast cells stimulated by the female sex hormone known as estrogen.
Arimidex 1 Tablet works by blocking the aromatase enzyme, which is involved in producing the estrogen hormone. The cancer cells require estrogen for their growth. Hence, by blocking the aromatase enzyme, Arimidex 1 Tablet prevents the growth of cancer cells. Together, Arimidex 1 Tablet helps prevent or stop the growth of tumours (cancer cells) in other body parts.
Take Arimidex 1 Tablet as prescribed by your doctor. Depending on your medical conditions, you are advised to take Arimidex 1 Tablet for as long as your doctor prescribes it. In some cases, you may experience common side effects such as headache, musculoskeletal (bone, muscle, or joint) pain, hot flashes, nausea, skin rashes, osteoporosis, and weakness. Do not hesitate to talk with your doctor if you persistently experience any of these side effects.
To treat your condition effectually, continue taking Arimidex 1 Tablet for as long as your doctor has prescribed. Do not stop Arimidex 1 Tablet midway. Talk to your doctor before taking Arimidex 1 Tablet if you have allergies, osteoporosis (thinning of bones), bone fractures, high levels of cholesterol, or severe liver or kidney disease. Avoid taking Arimidex 1 Tablet if you are pregnant or breastfeeding. Arimidex 1 Tablet causes weakness and dizziness, so drive only if you are alert. Arimidex 1 Tablet should not be given to children as safety has not been established. Avoid consuming alcohol with Arimidex 1 Tablet as it could lead to increased drowsiness and dizziness. Inform your doctor about your health condition and medications before taking Arimidex 1 Tablet to rule out any side effects.
arma-drugs.com/articles/2017-12-05/arimidex-1-street-price-8000���360077/View MoreArimidex 1 Tablet is a medication used to treat breast cancer in women who have gone through menopause (cessation of period periods). Breast cancer is a type of cancer that develops in (a) breast cells stimulated by the female sex hormone estrogen, such as by the promotion of the development of breast cancers in women who have had menopause, and (b) during the menopausal transition, the body contains less estrogen than it would otherwise take during the sexually active years. The cancer cells need estrogen for their growth. Arimidex 1 Tablet aids in preventing the growth of tumours (cancer cells) in other body parts.
However, not everyone who takes Arimidex 1 Tablet will experience side effects. Side effects can include hot flashes, joint pain, muscle aches, weakness, osteoporosis, and depression. Talk to your doctor if you suffer from any of these side effects.
If you are over 35 and have high levels of prolactin, then discuss with your doctor how Arimidex 1 Tablet can affect your menstrual cycle. Arimidex 1 Tablet may decrease the amount of estradiol in your breast milk, so your doctor will need to monitor your prolactin level while taking Arimidex 1 Tablet. If you experience hot flashes, dizziness, or joint pain while taking Arimidex 1 Tablet, talk to your doctor immediately. You should see your doctor immediately if you experience any of the following side effects: breast pain, tenderness, weakness, or swelling.
Arimidex 1 Tablet is a medication used to treat breast cancer in women who have gone through menopause (cessation of periods). Breast cancer is a type of cancer that develops in (a) breast cells stimulated by the female sex hormone estrogen, such as by the promotion of the development of breast cancers in women who have had menopause (cessation of periods). Thus, Arimidex 1 Tablet prevents the growth of cancer cells. Together, Arimidex 1 Tablet helps prevent the growth of tumours (cancer cells) in other body parts.
If you are taking Arimidex 1 Tablet, inform your doctor before taking Arimidex 1 Tablet. Your doctor will need to monitor your prolactin level while taking Arimidex 1 Tablet.
Anastrozole is approved to treat breast cancer in women who have undergone a previous mammary resection or oophorectomy. The drug is also approved to treat patients with advanced breast cancer who have been diagnosed after a surgery in the past. Arimidex (anastrozole) is the most common agent used for post-menopausal women with breast cancer. Arimidex is the only drug approved to treat post-menopausal women with cancer after menopause. Arimidex also has been shown to reduce the risk of breast cancer recurrence and disease progression in postmenopausal women. This drug is also approved for the treatment of patients who have had a previous major surgery or breast cancer recurrence before the previous operation. Arimidex is also approved to be used in patients with an intact uterus for the treatment of patients with a uterus that has not been removed in the past. Arimidex was first approved by the FDA in 1995. Since then, Arimidex has been approved in a number of other indications as well. Other than that, the drug is not approved for the treatment of women who have or have ever had endometriosis, pelvic or abdominal cancer, ovarian cancer, or any other cancer after menopause. Arimidex is not approved for the treatment of women who have or have ever had endometriosis, pelvic or abdominal cancer, ovarian cancer, or any other cancer after menopause. Arimidex is also not approved for the treatment of women who have or have ever had endometrial cancer. Arimidex is not approved for the treatment of women who have or have ever had endometrial cancer, a type of cancer that occurs when the lining of the uterus (endometrium) grows outside of the uterus (endometrium).
Stade de France Pharmacy